Ankaferd® Kanama Durdurucunun Rat Abdominal Aort Kanama Modelinde Kanama Zamanına Etkisi

Abstract

Giriş: Topikal hemostatik ajanların birçok cerrahi alanda kullanımı son yıllarda popularite kazanmıştır. Ankaferd^® kanama durdurucu (ABS) ajanın ratlarda abdominal aort cerrahisinde kanama zamanını kısaltıp, kanama miktarını azaltabildiğini belirt          meye amaçladık.

Hastalar ve Yöntem: Toplam 40 rat random 4 gruba (her grup n= 10) ayrıldı. Grup 1 ve grup 2’deki ön-tedavi almayan ratlara salin ve Ankaferd kanama durdurucu ABS emdirilmiş gaz uygulanırken, 5 gün asetil salisilik asit ve klopidgrel tedavisi alış olan grup 3 ve 4’teki ratlara da salin ve ABS emdirilmiş gaz uygulandı. İliak bifurkasyonun üzerinde abdominal aortaya 1 mm’lik bir kesi yapıldı. Ortalama kanama zamanı ve ortalama kanama miktarı belirlenip karşılaştırıldı.

Bulgular: Ratların yaş, ağırlık ve laboratuvar sonuçları karşılaştırıldığında gruplar arası anlamlı farklılık yoktu. ABS emdirilmiş gaz kullanılan hem tedavi uygulanmış hem de tedavi uygulanmamış gruplarda daha kısa kanama zamanı ve daha az kanama miktarı tespit edildi. Aradaki fark istatistiksel olarak anlamlı bulundu.

Sonuç: Ankaferd^® kanama durdurucunun major aort cerrahisi sonrası daha kısa kanama zamanı sağlama ve operasyon sonrası daha az kan kaybı sağlama potansiyeline sahiptir.

Keywords

• Topikal hemostaz,abdominal aort

Haemostatic Effects of Topical Ankaferd Blood Stopper® On Bleeding Time in A Rat Abdominal Aortic Bleeding Model

Abstract

Introduction: The use of topical haemostatic agents has been popularised in recent years in many areas of surgery. We aimed to determine whether Ankaferd blood stopper^® (ABS) can shorten the bleeding time and decrease the amount of bleeding in a rat abdominal aortic bleeding model.

Patients and Methods: A total of 40 rats were randomly divided into four groups (n= 10 in each group). Saline- and ABS-soaked gauzes were applied to rats that had not received any pre-treatment in Groups 1 and 2, while saline- and ABS-soaked gauzes were applied to rats that had received acetylsalicylic acid plus oral clopidrogel for 5 days in Groups 3 and 4. An incision of about 1 mm was made over the aorta just proximal to the iliac bifurcation. Mean bleeding time (MBT) and mean bleeding amount (MBA) were determined and compared.

Results: There were no significant differences in the age, weight and blood sample laboratory results of rats. Shorter MBT and less MBA were determined in ABS-soaked groups and the differences were statistically significant.

Conclusion: Ankaferd blood stopper^® has the potential to reduce the bleeding time and post-operative blood loss after a major aortic surgery.

Keywords

• Topical haemostasis,abdominal aorta

References

1. 1. Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. Ann Surg 2010;251:217-28.
2. 2. Sileshi B, Achneck HE, Lawson JH. Management of surgical hemostasis: topical agents. Vascular 2008;16:S22-8.
3. 3. Haznedaroglu BZ, Beyazit Y, Walker SL, Haznedaroglu IC. Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat. Crit Rev Oncol Hematol 2012;83:21-34.
4. 4. Aktas A, Er N, Onur MA. Effects of Ankaferd Blood Stopper (R) on vascular response in rat carotid artery. UHOD 2010;20:156-62.
5. 5. Kandemir O, Buyukates M, Kandemir NO, Aktunc E, Gul AE, Gul S, et al. Demonstration of the histopathological and immunohistochemical effects of a novel hemostatic agent, Ankaferd Blood Stopper, on vascular tissue in a rat aortic bleeding model. J Cardiothorac Surg 2010;5:110.
6. 6. Abacıoğlu S, Aydın K, Büyükcam F, Kaya U, Işık B, Karakılıç ME. Comparison of the efficiencies of buffers containing Ankaferd and chitosan on hemostasis in an experimental rat model with femoral artery bleeding. Turk J Haematol 2015 Apr 27.
7. 7. Karasoy Yeşilada A, Bayraktaroğlu SB, Sevim KZ, Sakız D, Tatlıdede HS. The efficacy of the hemostatic agent Ankaferd blood stopper on end-to-end unilateral sleeve fish-mouth anastomosis. Acta Orthop Traumatol Turc 2014;48:92-7.
8. 8. Saçak B, Akdeniz ZD, Şirinoğlu H, Çilingir ÖT, Çelebiler ÖB, Ercan F, et al. Microvascular anastomosis using Ankaferd blood stopper: demonstration of long-term histopathologic effects on vascular tissue. Blood Coagul Fibrinolysis 2014;25:721-5.

9. 9. Çakarer S, Eyüpoğlu E, Günes ÇÖ, Küseoğlu BG, Berberoğlu HK, Keskin C. Evaluation of the hemostatic effects of Ankaferd blood stopper during dental extractions in patients on antithrombotic therapy. Clin Appl Thromb Hemost 2013;19:96-9.
10. 10. Beyazit Y, Kart T, Kuscu A, Arslan A, Kurt M, Aktas B, et al. Successful management of bleeding after dental procedures with application of blood stopper: a single center prospective trial. J Contemp Dent Pract 2011;12:379-84.
11. 11. Iynen I, Bozkus F, San I, Alatas N. The hemostatic efficacy of Ankaferd Blood Stopper in adenoidectomy. Int J Pediatr Otorhinolaryngol 2011;75:1292-5.
12. 12. Guler M, Maralcan G, Kul S, Baskonus I, Yilmaz M. The efficacy of Ankaferd Blood Stopper for the management of bleeding following total thyroidectomy. J Invest Surg 2011;24:205-10.
13. 13. Meric Teker A, Korkut AY, Kahya V, Gedikli O. Prospective, randomized, controlled clinical trial of Ankaferd Blood Stopper in patients with acute anterior epistaxis. Eur Arch Otorhinolaryngol 2010;267:1377-81.
14. 14. Turhan N, Bilgili H, Captug O, Kurt M, Shorbagi A, Beyazit Y, et al. Evaluation of a haemostatic agent in rabbits. Afr J Tradit Complement Altern Med 2011;8:61-5.
15. 15. Nazli Y, Colak N, Alpay MF, Haltas H, Aksoy ON, Akkaya IO, et al. Assessment of the efficacy of Ankaferd blood stopper on the prevention of postoperative pericardial adhesions. Cardiovasc J Afr 2014;25:100-5.
16. 16. Mihmanli A, Ulker Z, Alpsoy L, Ezirganli S. Evaluation of cytotoxicity of a new hemostatic agent Ankaferd Blood Stopper® using different assays. Hum Exp Toxicol 2012;31:780-